688363 Stock Overview
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Bloomage BioTechnology Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥48.68 |
| 52 Week High | CN¥84.59 |
| 52 Week Low | CN¥44.72 |
| Beta | 0.88 |
| 1 Month Change | -19.75% |
| 3 Month Change | -17.01% |
| 1 Year Change | -27.23% |
| 3 Year Change | -65.05% |
| 5 Year Change | -47.32% |
| Change since IPO | -42.80% |
Recent News & Updates
Here's Why Bloomage BioTechnology (SHSE:688363) Has A Meaningful Debt Burden
Dec 29
Bloomage BioTechnology (SHSE:688363) Will Want To Turn Around Its Return Trends
Dec 13Why Bloomage BioTechnology's (SHSE:688363) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 06Recent updates
Here's Why Bloomage BioTechnology (SHSE:688363) Has A Meaningful Debt Burden
Dec 29Bloomage BioTechnology (SHSE:688363) Will Want To Turn Around Its Return Trends
Dec 13Why Bloomage BioTechnology's (SHSE:688363) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 06After Leaping 40% Bloomage BioTechnology Corporation Limited (SHSE:688363) Shares Are Not Flying Under The Radar
Sep 30Need To Know: Analysts Just Made A Substantial Cut To Their Bloomage BioTechnology Corporation Limited (SHSE:688363) Estimates
Aug 30Bloomage BioTechnology Corporation Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 27Bloomage BioTechnology (SHSE:688363) Seems To Use Debt Quite Sensibly
Jun 02Weak Statutory Earnings May Not Tell The Whole Story For Bloomage BioTechnology (SHSE:688363)
May 06Getting In Cheap On Bloomage BioTechnology Corporation Limited (SHSE:688363) Might Be Difficult
May 01Shareholder Returns
| 688363 | CN Personal Products | CN Market | |
|---|---|---|---|
| 7D | -3.2% | -2.9% | -1.1% |
| 1Y | -27.2% | -16.3% | 4.2% |
Return vs Industry: 688363 underperformed the CN Personal Products industry which returned -16.3% over the past year.
Return vs Market: 688363 underperformed the CN Market which returned 4.2% over the past year.
Price Volatility
| 688363 volatility | |
|---|---|
| 688363 Average Weekly Movement | 5.3% |
| Personal Products Industry Average Movement | 5.5% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in CN Market | 11.2% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 688363 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688363's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 4,417 | Yan Zhao | www.bloomagebioactive.com |
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names.
Bloomage BioTechnology Corporation Limited Fundamentals Summary
| 688363 fundamental statistics | |
|---|---|
| Market cap | CN¥23.22b |
| Earnings (TTM) | CN¥440.18m |
| Revenue (TTM) | CN¥5.73b |
52.9x
P/E Ratio4.1x
P/S RatioIs 688363 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688363 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.73b |
| Cost of Revenue | CN¥1.53b |
| Gross Profit | CN¥4.20b |
| Other Expenses | CN¥3.76b |
| Earnings | CN¥440.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 11, 2025
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 73.25% |
| Net Profit Margin | 7.68% |
| Debt/Equity Ratio | 1.8% |
How did 688363 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield42%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/13 08:34 |
| End of Day Share Price | 2025/01/13 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bloomage BioTechnology Corporation Limited is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fang Yi Cai | Changjiang Securities Co. LTD. |
| Xiyue Zhang | Chasing Securities |
| Jian Jun Zou | Chasing Securities |